Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A phase III trial has suggested that MedImmune's investigational influenza vaccine, CAIV-T, was more effective in preventing flu in children than the usual flu shot.
Subscribe to our email newsletter
CAIV-T, MedImmune’s latest generation of its FluMist nasal spray, was shown to be 55% more effective than the traditional shot in reducing influenza in children six months to 59 months of age.
The influenza attack rate was 8.6% for study participants receiving the flu shot compared to 3.9% for those who received the new nasal spray. The data also showed the spray provided statistically significant improvements in reducing influenza illness caused by both matched and mismatched A strains as compared to the flu shot.
“The objective of this CAIV-T trial was to demonstrate better and broader protection against influenza illness compared to the flu shot in young children,” stated Dr Robert Walker, vice president of clinical development at MedImmune. “We anticipate submitting these data to the FDA by the end of June 2006 to seek an expansion of our label to include children from five years down to six months of age.”